| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8477659 | Molecular and Cellular Endocrinology | 2012 | 11 Pages |
Abstract
⺠Despite castration, prostate cancer remains driven by the androgen receptor (AR) signaling axis. ⺠Mechanisms of resistance include tumor androgen synthesis and constitutively active AR variants. ⺠Novel agents targeting ligand synthesis and AR activation have demonstrated striking responses. ⺠Biomarkers for rational stratification of men to optimal treatment strategies are required. ⺠The AR axis remains the most attractive therapeutic target for advanced prostate cancer.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cell Biology
Authors
Sean M. Green, Elahe A. Mostaghel, Peter S. Nelson,